Pancreatitis: A potential complication of liraglutide?;Pancreatitis: ¿Una Complicación Potencial de Liraglutida?

Annals of Pharmacotherapy

Volumn 46, Issue 11, 2012, Pages 1547-1553

  Franks, Andrea S ^a,b   Lee, Phillip H ^c,d   George, Christa M ^a,e  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

^d EAST TENNESSEE STATE UNIVERSITY   (United States)

^e UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Adverse effects; Drug induced pancreatitis; Glucagon like peptide 1 agonist; Glucagon like peptide 1 analogue; Liraglutide; Pancreatitis

Indexed keywords

GLIMEPIRIDE; LIRAGLUTIDE; ROSIGLITAZONE;

ACUTE PANCREATITIS; BODY MASS; CHOLECYSTITIS; CHOLELITHIASIS; CHRONIC PANCREATITIS; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); COMORBIDITY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG WITHDRAWAL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREATITIS; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TREATMENT DURATION;

DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; PANCREATITIS;

EID: 84869217643     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q789     Document Type: Review

References (35)

1. Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. Am J Gastroenterol 2006;101:2379-400. doi: 10.1111/j.1572-0241.2006.00856.x
2. Lowenfels AB, Maisonneuve P, Sullivan T. The changing character of acute pancreatitis: epidemiology, etiology, and prognosis. Curr Gastroenterol Rep 2009;11:97-103. doi: 10.1007/s11894-009-0016-4
3. AGA Institute. AGA Institute technical review on acute pancreatitis. Gastroenterology 2007;132:2022-44. doi: 10.1053/j.gastro.2007.03.065
4. Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S. Druginduced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol 2007;5:648-61. doi: 10.1016/j.cgh.2006.11.023
5. Balani AR, Grendell JH. Drug-induced pancreatitis: incidence, management and prevention. Drug Safe 2008;31:823-37. doi: 10.2165/0002018-200831100-00002
6. Neumiller JJ, Campbell RK. Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Ann Pharmacother 2009;43: 1433-44. doi: 10.1345/aph.1M134
7. Joffe D. Liraglutide: a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus. Am J Health Syst Pharm 2010;67: 1326-36. doi: 10.2146/ajhp090230
8. Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care 2011;34:S279-84. doi: 10.2337/dc11-s23
9. Information for healthcare professionals: exenatide (marketed as Byetta). August 2008 update. August 8, 2008. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm (accessed 2012 Jul 15).
10. Denker PS, Dimarco PE. Exenatide (exendin- 4) induced pancreatitis: a case report (letter). Diabetes Care 2006;29:471.
11. Ayoub WA, Ashock AK, Hossam SN, Taylor HC. Exenatide-induced acute pancreatitis. Endocr Pract 2010;16:80-3. doi: 10.4158/EP09104.CRR
12. Anderson SL, Trujillo JM. Association of pancreatitis with glucagon-like peptide-1 agonist use. Ann Pharmacother 2010;44:904-9. doi: 10.1345/aph.1M676
13. Marre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD -1 SU). Diabet Med 2009;26:268-78. doi: 10.1111/j.1464-5491.2009.02666.x
14. Nauck M, Frid A, Hermansen K, et al. LEAD -2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84-90. doi: 10.2337/dc08-1355
15. Garber A, Henry R, Ratner R, et al. LEAD -3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD -3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-81. doi: 10.1016/S0140-6736(08)61246-5
16. Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B. LEAD -3 (Mono) Study Group. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab 2011;13:348-56. doi: 10.1111/j.1463-1326.2010.01356.x
17. Zinman B, Gerich J, Buse JB, et al. LEAD - 4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD -4 Met+TZD). Diabetes Care 2009;32:1224-30. doi: 10.2337/dc08-2124
18. Russell-Jones D, Vaag A, Schmitz O, et al. LEAD -5 Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD -5 met+SU): a randomised controlled trial. Diabetologia 2009;52:2046-55. doi: 10.1007/s00125-009-1472-y
19. Buse JB, Rosenstock J, Sesti G, et al. LEAD -6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD -6). Lancet 2009;374:39-47. doi: 10.1016/S0140-6736(09)60659-0
20. FDA Brief Report. Liraglutide (injection) NDA 22-341. Endocrine and Metabolic Drug Advisory Committee. Novo Nordisk, April 2, 2009. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeeting Materials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ UCM148659.pdf (accessed 2012 Jul 15).
21. Pratley RE, Nauck M, Bailey T, et al. The 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26- week, randomised, parallel-group, open-label trial. Lancet 2010;375: 1447-56.
22. Pratley R, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomized, parallel-group open label trial. Int J Clin Pract 2011;65:397-407. doi: 10.111/j.1742-1241.2011.02656.x
23. Lee PH, Stockton MD, Franks AS. Acute pancreatitis associated with liraglutide. Ann Pharmacother 2011;45:e22. doi: 10.1345/aph.1P714
24. Knezevich E, Crnic T, Kershaw S, Drincic A. Liraglutide-associated acute pancreatitis. Am J Health Syst Pharm 2012;69:386-9. doi: 10.2146/ajhp110221
25. Steinberg WM. Comment: acute pancreatitis associated with liraglutide. Ann Pharmacother 2011;45:1169. doi: 10.1345/aph.1P714a
26. Nachnani JS, Bulchandani DG, Nookala A, et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 2010;53:153-9. doi: 10.1007/s00125-009-1515-4
27. Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dray SM, Butler PC. Chronic GLP-1 receptor activation by exendin- 4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the KRAS G12D mouse model. Diabetes 2012;61:1-13.
28. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150-6. doi: 10.1053/j.gastro.2011.02.018
29. Noel R, Braun D, Patterson R, Bloomgren G. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009;32:834-8. doi: 10.2337/dc08-1755
30. Mallick S. Metformin induced acute pancreatitis precipitated by renal failure. Postgrad Med J 2004;80:239-40. doi: 10.1136/pgmj.2003.011957
31. FDA drug safety communication. Victoza (liraglutide [rDNA origin]) injection: REMS risk of thyroid C-cell tumors, acute pancreatitis. June 13, 2011. www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm258826.htm (accessed 2012 Jul 15).
32. Risk Evaluation and Mitigation Strategy (REMS). NDA 22-341 VICTOZA (liraglutide [rDNA origin] injection). Princeton, NJ: Novo Nordisk Inc., May 2011.
33. Package insert. Victoza (liraglutide). Princeton, NJ: Novo Nordisk, May 18, 2011.
34. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
35. Famularo G, Gasbarrone L, Minisola G. Pancreatitis during treatment with liraglutide. JOP 2012;13:540-1. doi: 10.6092/1590-8577/1107